MX2022007926A - Coagonistas lactamicos grapados de los receptores de glucagon y glp-1. - Google Patents

Coagonistas lactamicos grapados de los receptores de glucagon y glp-1.

Info

Publication number
MX2022007926A
MX2022007926A MX2022007926A MX2022007926A MX2022007926A MX 2022007926 A MX2022007926 A MX 2022007926A MX 2022007926 A MX2022007926 A MX 2022007926A MX 2022007926 A MX2022007926 A MX 2022007926A MX 2022007926 A MX2022007926 A MX 2022007926A
Authority
MX
Mexico
Prior art keywords
glp
glucagon
agonists
receptors
stapled
Prior art date
Application number
MX2022007926A
Other languages
English (en)
Inventor
Songnian Lin
Anandan Palani
Qiaolin Deng
Federica Orvieto
Elisabetta Bianchi
Paul E Carrington
Antonello Pessi
Tomi K Sawyer
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022007926A publication Critical patent/MX2022007926A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los péptidos grapados de la presente invención, y sales farmacéuticamente aceptables de los mismos, son coagonistas de los receptores de glucagón y GLP-1, y pueden ser útiles en el tratamiento, prevención y supresión de enfermedades mediadas por el receptor de glucagón y el receptor de GLP-1, que incluyen, pero no se limitan a, trastornos metabólicos tales como diabetes, enfermedad del hígado graso no alcohólico (NAFLD), esteatohepatitis no alcohólica (NASH) y obesidad.
MX2022007926A 2019-12-23 2020-12-18 Coagonistas lactamicos grapados de los receptores de glucagon y glp-1. MX2022007926A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19425096.5A EP3842060A1 (en) 2019-12-23 2019-12-23 Stapled lactam co-agonists of the glucagon and glp-1 receptors
PCT/US2020/065791 WO2021133642A1 (en) 2019-12-23 2020-12-18 Stapled lactam co-agonists of the glucagon and glp-1 receptors

Publications (1)

Publication Number Publication Date
MX2022007926A true MX2022007926A (es) 2022-09-29

Family

ID=69326340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007926A MX2022007926A (es) 2019-12-23 2020-12-18 Coagonistas lactamicos grapados de los receptores de glucagon y glp-1.

Country Status (10)

Country Link
US (1) US20230285514A1 (es)
EP (2) EP3842060A1 (es)
JP (1) JP2023508347A (es)
KR (1) KR20220119474A (es)
CN (1) CN114867742A (es)
AU (1) AU2020415355A1 (es)
BR (1) BR112022012335A2 (es)
CA (1) CA3162379A1 (es)
MX (1) MX2022007926A (es)
WO (1) WO2021133642A1 (es)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU6691498A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2000014095A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
ES2250128T3 (es) 1999-05-17 2006-04-16 Novo Nordisk A/S Antagonistas/agonistas inversos de glucagon.
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
EP1357908A4 (en) 2001-01-30 2009-07-15 Merck & Co Inc ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
AU2006258841B2 (en) 2005-06-13 2012-05-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
WO2008010017A1 (en) 2006-07-19 2008-01-24 Freescale Semiconductor, Inc. Method and apparatus for designing an integrated circuit
US8454971B2 (en) * 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AU2008267724A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd Substituted fused pyrimidines as antagonists of GPR105 activity
WO2009001836A1 (en) 2007-06-28 2008-12-31 Semiconductor Energy Laboratory Co., Ltd. Manufacturing method of semiconductor device
CA2693214A1 (en) 2007-07-19 2009-01-22 Merck Sharp & Dohme Corp. Beta carboline derivatives as antidiabetic compounds
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
US8546327B2 (en) 2008-06-17 2013-10-01 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2525809B1 (en) * 2010-01-20 2016-08-03 Zealand Pharma A/S Glucagon-glp1 dual agonists for use in the treatment of cardiac conditions
KR20130111923A (ko) * 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
WO2013074910A1 (en) * 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP3209682B1 (en) 2014-10-24 2020-12-30 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
WO2017100107A2 (en) * 2015-12-09 2017-06-15 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
AU2018338184B2 (en) 2017-09-25 2023-04-13 Merck Sharp & Dohme Llc Long-acting co-agonists of the glucagon and GLP-1 receptors
CN115109166A (zh) * 2017-11-24 2022-09-27 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN109836488B (zh) * 2017-11-24 2022-08-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物

Also Published As

Publication number Publication date
BR112022012335A2 (pt) 2022-08-30
EP4081535A1 (en) 2022-11-02
CN114867742A (zh) 2022-08-05
EP4081535A4 (en) 2024-02-28
EP3842060A1 (en) 2021-06-30
WO2021133642A1 (en) 2021-07-01
AU2020415355A1 (en) 2022-06-30
JP2023508347A (ja) 2023-03-02
CA3162379A1 (en) 2021-07-01
KR20220119474A (ko) 2022-08-29
US20230285514A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
PH12017500761A1 (en) Co-agonists of glucagon and glp-1 receptors
PH12020551025A1 (en) Incretin analogs and uses thereof
PH12020551024A1 (en) Incretin analogs and uses thereof
PH12017502359A1 (en) Glucagon and glp-1 co-agonist compounds
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
MX2015010935A (es) Compuestos biciclicos antidiabeticos.
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
MX2016015182A (es) Compuestos triciclicos antidiabeticos.
MX2015001500A (es) Compuestos antidiabeticos triciclicos.
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
EA202091464A1 (ru) Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита
MX2023008330A (es) Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
MX2022003251A (es) Anticuerpo contra gipr y su proteina de fusion con glp-1, y composicion farmaceutica y aplicacion de los mismos.
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
MX2022007929A (es) Coagonistas de triazol grapados de los receptores de glucagon y glp-1.
WO2016168388A3 (en) Therapies for obesity, diabetes and related indications
MX2022007926A (es) Coagonistas lactamicos grapados de los receptores de glucagon y glp-1.
MX2022007928A (es) Co-agonistas de olefina engrapados de los receptores de glucagon y glp-1.
MX2022013230A (es) Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis.
WO2015051234A3 (en) Tweak antagonists for treating lupus nephritis and muscle atrophy
TH1701002228A (th) อะโกนิสต์ร่วมของกลูคากอนและ glp-1 รีเซปเตอร์
MX2020011960A (es) Nuevo compuesto que presenta actividad inhibidora de enteropeptidasa.
EA201990883A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения